Crinetics Pharmaceuticals Inc (CRNX) - News Archive

In a decisive move aimed at bolstering its workforce and attracting top-tier talent, Crinetics Pharmaceuticals, a leading player in the biopharmaceutical industry, announced on April 10, 2025, that its Compensation Comm...

In a significant move to bolster its workforce, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) has announced the issuance of inducement grants to 14 new non-executive employees, a decision that strategically aligns with...

Crinetics Pharmaceuticals Announces Inducement Grants to New Employees Amid Growth StrategyOn January 10, 2025, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a biotechnology firm focused on developing therapies for en...

Crinetics Pharmaceuticals Awards Stock Options to New Non-Executive Employees Amid Promising Developments in Neuroendocrine Tumor TreatmentOn December 10, 2024, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced s...

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting Crinetics Pharmaceuticals, a leading in...

Crinetics Pharmaceuticals Welcomes New Talent Amid Strategic Moves and Public Offering PlansSAN DIEGO, Oct. 10, 2024 In a series of calculated strategic maneuvers, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) has anno...

Crinetics Pharmaceuticals: A Strategic Leap into the Future with a Robust Public OfferingIn a significant move that underscores its commitment to growth and innovation, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a...

Crinetics Pharmaceuticals Moves Forward with $400 Million Stock Offering Amid Growth InitiativesCrinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company dedicated to developing innovative...

nnCrinetics Pharmaceuticals Expands Workforce with September 2024 Inducement GrantsnnSAN DIEGO, Sept. 10, 2024nn Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) continues to grow its team and incentivize new talent by is...

In the rapidly evolving landscape of pharmaceutical innovation, patient education increasingly emerges as a vital component of treatment. Crinetics Pharmaceuticals, a clinical-stage company focused on developing novel t...

Crinetics Pharmaceuticals Grants Stock Options to New Employees, Continues to Make Waves in Endocrine Treatment IndustryIn a recent press release from Crinetics Pharmaceuticals, Inc., it was announced that the Compensat...

Crinetics Pharmaceuticals Enhances Talent Acquisition with Strategic Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, June 10, 2024 In a strategic move to attract top-tier talent, Crinetics Pharmaceutic...

Crinetics Presents Compelling Data Highlighting Potential of Paltusotine in Treating Acromegaly and Carcinoid SyndromeCrinetics Pharmaceuticals has recently unveiled promising data at ENDO 2024, providing further eviden...

In a recent announcement, Crinetics Pharmaceuticals, a clinical-stage pharmaceutical company dedicated to addressing endocrine diseases and endocrine-related tumors, informed the public that the late-breaking abstracts...

Crinetics Pharmaceuticals Grants Stock Options to New Employees and Closes Oversubscribed $350 Million Private PlacementSAN DIEGO, April 11, 2024 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) made two significant ann...

Crinetics Pharmaceuticals, a clinical-stage biotechnology company focused on developing innovative therapeutics for rare endocrine diseases and endocrine-related tumors, has announced promising results from two separate...

Crinetics Announces Positive Results for Paltusotine in Phase 2 Trial for Carcinoid Syndrome Treatment - In a recent press release, Crinetics Pharmaceuticals reported positive topline results from its Phase 2 trial of p...

Crinetics Pharmaceuticals Continues Growth with March 2024 Inducement Grants Following Successful Public Offering in 2023In recent news, Crinetics Pharmaceuticals, a leading biotechnology company focused on developing n...

Crinetics Pharmaceuticals Raises $350 Million in Oversubscribed Private PlacementSan Diego-based clinical-stage pharmaceutical company, Crinetics Pharmaceuticals, announced today that it has successfully completed an ov...

San Diego-based pharmaceutical company, Crinetics Pharmaceuticals, Inc., recently announced the granting of non-qualified stock option awards to nine new non-executive employees. Under the Crinetics Pharmaceuticals, Inc...